Financial publications

 

The financial publications section contains the Company’s annual and quarterly reports, corporate presentations held at Investor Relations events as well as the Company’s financial guidance and financial key figures. Further information regarding the Company’s business model and its business segments can be found in the 'About' section of this website.

 

Financial Reports

Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations.

 

Financial Reports Archive

2019

Webcast/Conference call regarding the acquisition of Just.Bio

2018

Annual Report

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the fiscal year 2018 results

2017

Annual Report

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the fiscal year 2017 results

Conference Call/Webcast regarding the acquisition of Aptuit

2016

Financial Statements

Conference Call/Webcast regarding strategic collaboration with Celgene

Conference Call/Webcast regarding the offer to acquire Cyprotex

2014

Financial Statements

Conference Call/Webcast announcing negotiations on major collaboration with Sanofi

2011

Annual Report

Financial Statements

Conference call Webcast announcing licence argeement with Roche

Conference call and Webcast announcing the acquisition of Compound Focus, Inc.

Conference call and Webcast announcing the acquisition of Kinaxo

2010

Financial Statements

Conference call and Webcast announcing the alliance with MedImmune

Third Quarter Report

Half Year Report

Conference call and Webcast announcing the acquisition of DeveloGen

First Quarter Report

2009

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2008

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2007

Annual Report

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2006

Annual Report

Financial Statements According to HGB

Third Quarter Report

Second Quarter Report

First Quarter Report

2005

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

New Segmental P&L Statements

2004

Third Quarter Report

Second Quarter Report

First Quarter Report

2003

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2002

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2001

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2000

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

Oxford Asymmetry International plc 2000 Interim Statement

Oxford Asymmetry International plc 2000 Interim Statement

1999

Annual Report

Third Quarter Report

Oxford Asymmetry International plc Annual Report 1999

Guidance 2019

Guidance 2019
Actual 2018
Group revenues from contracts with customers without revenues from recharges
Approx. 15% growth (previously: approx 10%)1)
€ 364.0 m2)
Unpartnered R&D expenses
Approx. € 30-40 m (unchanged)
€ 22.9 m
Adjusted Group EBITDA3)
Improve by >10% compared to 2018 (previously: approx. 10%)
€ 92.0 m4)
Group revenues from contracts with customers without revenues from recharges  
Guidance 2019 Approx. 15% growth (previously: approx 10%)1)
Actual 2018 € 364.0 m2)
Unpartnered R&D expenses  
Guidance 2019 Approx. € 30-40 m (unchanged)
Actual 2018 € 22.9 m
Adjusted Group EBITDA3)  
Guidance 2019 Improve by >10% compared to 2018 (previously: approx. 10%)
Actual 2018 € 92.0 m4)

1) Based on current/updated FX rates

2) 2018 total revenues excluding revenues from recharges according to IFRS 15

3) EBITDA is defined as earnings before interest, taxes, depreciation, and amortisation of intangibles. Adjusted EBITDA excludes contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

4) 2018 total adjusted Group EBITDA excluding € 3.5 m one-off effects in 2018

Financial key figures 2018 according to IFRS

2018
2017
18|17 in %
Results1):
Revenues from contracts with customers
T€
375,405
263,765
42
R&D expenses
T€
(35,619)
(17,614)
102
Operating result
T€
77,463
36,727
111
Adjusted Group EBITDA2)
T€
95,457
57,222
67
Net income
T€
84,056
23,218
Balance sheet data3):
Total stockholders' equity
T€
424,880
331,915
28
Capital expenditure4)
T€
27,867
17,565
59
Cash, cash equivalents and investments
T€
149,449
91,156
64
Balance sheet total
T€
771,883
666,475
16
Operating cash flow
T€
156,240
10,828
Personnel data:
Employees as of 31 December
2,617
2,178
20
Per share:
Result (basic/diluted)
0.57/0.56
0.16/0.16
Results1):  
2018
2017
18|17 in %
Revenues from contracts with customers  
T€
2018 375,405
2017 263,765
18|17 in % 42
R&D expenses  
T€
2018 (35,619)
2017 (17,614)
18|17 in % 102
Operating result  
T€
2018 77,463
2017 36,727
18|17 in % 111
Adjusted Group EBITDA2)  
T€
2018 95,457
2017 57,222
18|17 in % 67
Net income  
T€
2018 84,056
2017 23,218
18|17 in %
 
2018
2017
18|17 in %
Balance sheet data3):  
2018
2017
18|17 in %
Total stockholders' equity  
T€
2018 424,880
2017 331,915
18|17 in % 28
Capital expenditure4)  
T€
2018 27,867
2017 17,565
18|17 in % 59
Cash, cash equivalents and investments  
T€
2018 149,449
2017 91,156
18|17 in % 64
Balance sheet total  
T€
2018 771,883
2017 666,475
18|17 in % 16
Operating cash flow  
T€
2018 156,240
2017 10,828
18|17 in %
 
2018
2017
18|17 in %
Personnel data:  
2018
2017
18|17 in %
Employees as of 31 December  
2018 2,617
2017 2,178
18|17 in % 20
 
2018
2017
18|17 in %
Per share:  
2018
2017
18|17 in %
Result (basic/diluted)  
2018 0.57/0.56
2017 0.16/0.16
18|17 in %

1) 2017 data adjusted for the first time application of IFRS 15 Revenue from Contracts with Customers

2) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

3) 2017 data adjusted for the first time application of IFRS 15 Revenue from Contracts with Customers as well as the finalisation of the purchase price allocation of the Aptuit Group

4) Cash-relevant purchase of tangible and intangible assets

 

Investor Presentations

Please find below various presentations held at investor conferences or during investor calls available for your download.

Downloads

German Corporate Conference 2018
(15 January 2018)PDF, 1.9 MB

BioCapital 2018
(06 February 2018)PDF, 1.4 MB

24th Prior Kapitalmarktkonferenz
(13 March 2018)PDF, 1.6 MB

Webcast/Conference call regarding the exclusive talks with Sanofi
(08 March 2018)PDF, 1.6 MB

H.C. Wainwright Global Life Sciences Conference
(09 April 2018)PDF, 1.5 MB

11th Kempen Life Sciences Conference (19 April 2018)PDF, 1.1 MB

Deutsche Bank 43rd Annual Health Care Conference (08 May 2018)PDF, 1.4 MB

Bank of America Merrill Lynch Health Care Conference 2018 (16 May 2018)PDF, 1.5 MB

Berenberg USA Conference 2018 (22 May 2018)PDF, 1.4 MB

Jefferies 2018 Global Healthcare Conference (05 June 2018)PDF, 1.6 MB

dbAccess Berlin Conference (07 June 2018)PDF, 1.4 MB

Bank of America Merrill Lynch Global Healthcare Conference 2018 (13 Sept 2018)PDF, 1.6 MB

Baader Investment Conference (24 Sept 2018)PDF, 1.6 MB

Berenberg and Goldman Sachs Seventh German Corporate Conference (26 Sept 2018)PDF, 1.6 MB

Cantor Global Healthcare Conference 2018 (02 Oct 2018)PDF, 1.6 MB

Jefferies London Healthcare Conference 2018 (14 Nov 2018)PDF, 1.8 MB

German Equity Forum 2018 (26 Nov 2018)PDF, 1.6 MB

37th J.P. Morgan Healthcare Conference (10 Jan 2019)PDF, 1.8 MB

18th German Corporate Conference 2019 (22 Jan 2019)PDF, 1.8 MB

BioCapital Europe 2019 (14 March 2019)PDF, 1.5 MB

H.C. Wainwright Global Life Sciences Conference (08 April 2019)PDF, 1.5 MB

Kempen & Co Life Sciences Conference (17 April 2019)PDF, 1.5 MB

Berenberg Conference USA 2019 (21 May 2019)PDF, 1.6 MB

2019 RBC Capital Markets Global Healthcare Conference (22 May 2019)PDF, 1.2 MB

dbAccess Berlin Conference 2019 (05 June 2019)PDF, 1.6 MB

European Small and Mid Cap Conference (06 June 2019)PDF, 2.1 MB

Jefferies 2019 Healthcare Conference (06 June 2019)PDF, 1.8 MB

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard
TOP